Search Results 451-460 of 15974 for SC

  1. Gastroenterology and Hepatology - Clinical trials

    The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

  2. Publications - Matthew R. Hopkins, M.D. - Mayo Clinic

    Richards EG, El-Nashar SA, Schoolmeester JK, Keeney GL, Mariani A, Hopkins MR, Dowdy SC, Daftary GS, Famuyide AO. Abnormal Uterine Bleeding Is Associated ...

  3. Gastroenterology and Hepatology - Clinical trials

    The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

  4. Gastroenterology and Hepatology - Clinical trials

    The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

  5. #FlashbackFriday 1986: Opening the Florida campus - Mayo Clinic News Network

    Johnson, chairman and chief executive officer of S.C. Johnson & Son, Inc., and chairman of the Mayo Foundation Board of Trustees; and J.E. Davis of ...

  6. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

    About this study. The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in ...

  7. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with ...

  8. Publications - Patrick B. Johnston, M.D., Ph.D. - Mayo Clinic

    ... SC. Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy. Blood Adv. 2024 Mar 12; 8 (5):1250 ...

  9. Pulmonary Hypertension Association Registry - Mayo Clinic

    Gerald; Mathai SC. Stephen C; Hassoun PM. Paul M; . . Pulmonary circulation. 2023. Jul; 13(3):e12281. The prevalence of acute vasodilator response (AVR) to ...

  10. Publications - Meera Sridharan, M.D., Ph.D. - Mayo Clinic

    ... SC, Sridharan M. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv. 2023 Feb ...